secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0001104659-23-040152
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode Therapeutics reports 2022 operating loss of $17.9M; cash runway into Q2 2023
--------------------------------------------------------------------------------

- Cash at Dec 31, 2022: $5.0M, down from $20.8M at Dec 31, 2021.
- Operating loss of $17.9M in 2022 vs $6.8M in 2021; R&D expense $10.5M (up from $2.8M).
- Cash of $5.0M plus $1.3M from Feb 2023 offering and $871k SBIR expected to fund into but not through Q2 2023.
- FDA authorized Phase 0 FIH trial for lead candidate TTX-MC138 in advanced solid tumors.
- Strategic alliance with MD Anderson and Orphan Drug Designation for TTX-siPDL1 in pancreatic cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923040152/0001104659-23-040152-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923040152/tm2310837d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-040152

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer